Clinical studies with matrix metalloproteinase inhibitors
- 1 March 1999
- Vol. 107 (1-6) , 174-180
- https://doi.org/10.1111/j.1699-0463.1999.tb01541.x
Abstract
Matrix metalloproteinases (MMPs) have been implicated in the invasive growth and spread of tumours. Potent and selective inhibitors of MMPs have been synthesized. These inhibitors can prevent tumour invasion in vitro and have suppressed tumour growth and metastasis in animal cancer models. Several MMP inhibitors have now reached clinical trials. Phase I studies indicate that the inhibitors can be given by mouth and that over the short term they are well tolerated. Longer, randomised studies in cancer patients are now underway.Keywords
This publication has 19 references indexed in Scilit:
- Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteersBritish Journal of Clinical Pharmacology, 1998
- Cancer UndefeatedNew England Journal of Medicine, 1997
- Matrix metalloproteinase inhibitors in the treatment of cancerMedical Oncology, 1997
- Recent advances in matrix metalloproteinase inhibitor researchDrug Discovery Today, 1996
- Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic MiceJNCI Journal of the National Cancer Institute, 1995
- Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitorBiochemistry, 1995
- Low Molecular Weight Inhibitors in Corneal UlcerationaAnnals of the New York Academy of Sciences, 1994
- Structural biochemistry and activation of matrix metalloproteasesCurrent Opinion in Cell Biology, 1993
- A Non-antibacterial Chemically-modified Tetracycline Inhibits Mammalian Collagenase ActivityJournal of Dental Research, 1987